Loading...

PE anti-mouse CD152 Antibody

Pricing & Availability
Clone
UC10-4B9 (See other available formats)
Regulatory Status
RUO
Other Names
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), Ly-56
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
UC10-4B9_PE_090507
Con A+IL-2-stimulated BALB/c splenocytes (day-2) were stained with CD3 APC and UC10-4B9 PE
  • UC10-4B9_PE_090507
    Con A+IL-2-stimulated BALB/c splenocytes (day-2) were stained with CD3 APC and UC10-4B9 PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
106305 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
106306 200 µg 264€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
Mouse CTLA-4-mouse IgG2a fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro stimulation, in vitro and in vivo blocking1-4 of ligand binding, and as ELISA capture antibody5. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The Ultra LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 106327).

Application References
  1. Walunas TL, et al. 1994. Immunity 1:405. (Block, IP)
  2. Cilio CM, et al. 1998. J. Exp. Med. 188:1239. (Block)
  3. Issazadeh S, et al. 1999. J. Immunol. 162:761. (Block)
  4. McCoy K, et al. 1997. J. Exp. Med. 186:183. (Block)
  5. Hsu HC, et al. 2007. J. Immunol. 178:5357. (ELISA Capture)
  6. Sugita S, et al. 2010. Invest. Ophthalmol. Vis. Sci. 51:5783. PubMed
Product Citations
  1. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  2. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  3. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  4. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  5. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  6. Xu L et al. 2017. Immunity. 47(3):538-551 . PubMed
  7. Benci JL et al. 2019. Cell. 178(4):933-948 . PubMed
  8. DeLong JH, et al. 2019. Immunohorizons. 3:13. PubMed
  9. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  10. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  11. Ren J, et al. 2019. PLoS Biol. 17:e3000270. PubMed
  12. Shi B, et al. 2018. J Immunol. 200:586. PubMed
  13. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  14. Sugita S, et al. 2010. Invest Ophthalmol Vis Sci. 51:5783. PubMed
  15. Thauland T, et al. 2014. J Immunol. 193:5894. PubMed
  16. Singh K, et al. 2015. Sci Rep. 14:7767. PubMed
  17. Alikhan M, et al. 2016. J Am Soc Nephrol. 27: 706 - 714. PubMed
  18. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  19. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  20. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  21. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  22. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  23. Wei SC, et al. 2020. Cancer Discov. . PubMed
  24. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  25. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  26. An J, et al. 2022. iScience. 25:103570. PubMed
  27. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  28. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  29. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  30. Hu J, et al. 2022. J Immunother Cancer. 10:. PubMed
  31. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  32. Zhang GL, et al. 2020. Matrix Biol. 93:25. PubMed
  33. Rinaldi S, et al. 2021. PLoS Pathog. 17:e1009533. PubMed
  34. Elliot TAE, et al. 2021. Immunity. 54:2481. PubMed
  35. Zenke S, et al. 2022. Nat Commun. 13:6459. PubMed
  36. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  37. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  38. Broadfield LA, et al. 2022. Mol Metab. 61:101498. PubMed
  39. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  40. Ivasko SM, et al. 2023. Front Immunol. 13:1023206. PubMed
  41. Schwarz A, et al. 2023. Front Immunol. 14:1038689. PubMed
  42. Xiao X, et al. 2023. Nat Commun. 14:2859. PubMed
RRID
AB_313254 (BioLegend Cat. No. 106305)
AB_313255 (BioLegend Cat. No. 106306)

Antigen Details

Structure
Ig superfamily, 33 kD
Distribution

Activated T cells and B cells

Function
Negative regulator of T cell activation
Ligand/Receptor
CD80 (B7-1), CD86 (B7-2)
Cell Type
B cells, T cells, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Allison JP, et al. 1995. Science 270:932.
3. Waterhouse P, et al. 1995. Science 270:985.
4. Linsley PS, et al. 1991. J. Exp. Med. 174:561.

Gene ID
12477 View all products for this Gene ID
UniProt
View information about CD152 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 2    Revision Date: 04-18-2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account